Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study

Do you have cataracts? Did you ever take interferon? Hmmmm!!! Hepatitis C virus (HCV) infection is associated with increased systemic oxidative stress, which leads to cardiovascular events, diabetes, and chronic kidney disease. Similarly, cataract is also associated with increased oxidative stress. The association between HCV infection and increased risk of cataract remains unclear. In this study, we observed a positive association between pegylated in

Simeprevir (GALEXOS) now covered in Quebec as well!

Simeprevir (GALEXOS) is also now covered on the Quebec formulary, according to CATIE, the Canadian AIDS Treatment Information Exchange. However, it is only available to those who have already failed conventional treatment with interferon and ribavirin. It is available only to genotype 1 patients who do not have the Q80K mutation and not co-infected with HIV. MUST MEET ALL THESE QUALIFICATIONS TO GET REIMBURSED FOR SIMEPREVIR: -- to be used in association w